OralSurgery

- Dhaliwal H, McKaig S. Dentinogenesis imperfecta – clinical presentation and management. *Dent Update* 2010; 37: 364–371.
- Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998; 87: 64–68.
- Glorieux FH, Bishop NJ, Plotkin H et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947–952.
- Rauch F, Plotkin H, Travers R et al.
 Osteogenesis imperfecta types I, III and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003; 88: 986–992.
- Barker K, Rogers S. Biphosphonateassociated osteonecrosis of the jaws: a guide for the general dental practitioner. *Dent Update* 2006; 33: 270–275.
- Arrain Y, Masud T. Recent recommendations on bisphosphonate-associated osteonecrosis of the jaw. *Dent Update* 2008; 35: 238–242.
- Arrain Y, Masud T. Bisphosphonates and osteonecrosis of the jaw – current thoughts. Dent Update 2009; 36: 415–419.
- 9. Brock G, Barker K, Butterworth CJ et al.

- Practical considerations for treatment of patients taking bisphosphonate medications: an update. *Dent Update* 2011; **38**: 313–326.
- Arrain Y, Masud T. A current update on osteonecrosis of the jaw and bisphosphonates. *Dent Update* 2011; 38: 672–678.
- Khosla S, Burr D, Cauley J et al.
 Bisphosphonate-associated osteonecrosis of
 the jaw: report of a taskforce of the American
 Society for Bone and Mineral Research. J Bone
 Miner Res 2007; 70: 224–236.
- Chahine C, Cheung MS, Head TW et al. Tooth extraction socket healing in paediatric patients treated with intravenous pamidronate. J Pediatrics 2008; 153: 719–720.
- Schwartz S, Joseph C, Iera D, Vu DD.
 Bisphosphonates, osteonecrosis,
 osteogenesis imperfecta and dental
 extractions: a case series. J Can Dent Assoc
 2008: 74: 537–542.
- Brown JJ, Ramalingam L, Zacharin MR.
 Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children? Clin Endocrinol 2008; 68: 863–867.
- Milano M, Wright T, Loechner KJ. Dental implications of osteogenesis imperfecta: treatment with IV bisphosphonate: report of

- a case. Pediatr Dent 2011; 33(4): 349-352.
- Grier RL IV, Wise GE. Inhibition of tooth eruption in the rat by a bisphosphonate. J Dent Res 1998; 77: 8–15.
- Kamoun-Goldrat A, Ginisty D, Le Merrer M. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfect. *Eur J Oral Sci* 2008; **116:** 195–198.
- Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 2012; 12(3): 183–188.
- 19 Diz P, Lopex-Cedrun JL, Arenaz J, Scully C. Denosumab-related osteonecrosis of the jaw. J Am Dent Assoc 2012; 143(9): 981–984.
- Troeltzsch M, Woodlock T, Kriegelstein S, Steiner T, Messlinger K. Physiology and pharmacology of non bisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc 2012; 78: c85.
- 21. Abela S, Chotai M, Bister D. What do you need to know about bisphosphonates: an overview and general recommendations for orthodontic treatment. *J Orthod* 2012; **39**(3): 234–236.

Book Review

Oral and Maxillofacial Medicine, the Basis of Diagnosis and Treatment 3rd edn. By Crispian Scully. Oxford: Churchill Livingstone Elsevier, 2013 (448pp; £49.99p/b). ISBN 978-0-7020-4948-4.

This book, from our most prodigious dental author, is now in its 3rd edition. Crispian Scully has set out ambitious aims to produce a text that will: i) aid the clinician in the diagnosis of the common as well as the more serious oral disorders; ii) suggest appropriate investigations to help confirm the diagnosis; and iii) provide management regimes and/or suggested referral pathways, to complete the patient care package.

To achieve these lofty aims there is much cross-referencing between chapters utilizing tables and algorithms: taking, for example, the single ulcer, the clinician can turn to section 2 (Common complaints), follow the appropriate algorithm and be led towards the more serious diagnosis in section 3 (Potentially malignant disorders),

or towards a non-neoplastic diagnosis with management regimes, found in section 4 (*Common and important orofacial conditions*). Examples of suitable 'patient information sheets', as well as useful websites, are provided at the end of each chapter for the benefit of both patient and clinician.


In an added attempt to keep the book contemporary and relevant, reference is made to emergent therapies and also complementary medicine products. At the end of each chapter, a reference section provides a further resource for those wishing to examine the evidence base underpinning this extensive work.

It is not surprising that previous editions of this book, that now runs to over 400 pages, have won awards and plaudits since it was first published in 2004.

To whom would I recommend this book? I would not necessarily recommend that this book needs to be read cover to cover unless it is of specialist interest, however, practising clinicians may need to justify why they do not own such a valuable reference book rather than why

they do. In the interest of your patients and your own erudition you would do well to have this tome close to hand in your office.

> Nick Malden Consultant, Oral Surgery Edinburgh Dental Institute



738 **Dental**Update November 2013